India’s first dengue vaccine arrives with a crucial safety caveat
Summary
Qdenga could be responsible for enhancing dengue in children who have not had an infection yet in their lives. In such cases, the vaccine could simulate a primary dengue infection in the body, resulting in protection against DENV-1 and DENV-2 infections but not against a DENV-3 infection
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For India, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketIndia
- ImpactMedium (50/100)
- SignalNews